At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 204 enrolled
Drug / intervention
Diclofenac sodium +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel (DSG) 1% Applied Four Times Daily in Subjects With Acute Blunt Soft Tissue Injuries/Contusions of the Limbs
In Brief
A Phase 3 clinical trial evaluating Diclofenac sodium and Placebo for Acute Blunt Soft Tissue Injuries/Contusions. Completed, enrolled 204 participants across 6 sites.
Detailed Summary
The purpose of this study is to evaluate the efficacy of DSG 1% compared with placebo applied four times a day in subjects with acute blunt soft tissue injuries/contusions of the limbs
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2011
First PostedJan 2011
Primary CompletionJul 2011
TodayJul 2026
First PostedJan 10, 2011
Enrollment StartJan 1, 2011
Primary CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 15.5 years ago
Interventions
Diclofenac sodiumdrug
Topical gel 1%- 4 times daily
Placeboother
Topical gel - 4 times daily